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Objectives: We evaluated the performance and time to result for pathogen identification (ID) and antimicrobial
susceptibility testing (AST) of the Accelerate PhenoTM system (AXDX) compared with standard of care (SOC)
methods. We also assessed the hypothetical improvement in antibiotic utilization if AXDX had been
implemented.
Methods: Clinical samples from patients with monomicrobial Gram-negative bacteraemia were tested and
compared between AXDX and the SOC methods of the VERIGENEV
R
and Bruker MALDI BiotyperV
R
systems for ID
and the VITEKV
R
2 system for AST. Additionally, charts were reviewed to calculate theoretical times to antibiotic
de-escalation, escalation and active and optimal therapy
Results: ID mean time was 21 h for MALDI-TOF MS, 4.4 h for VERIGENEV
R
and 3.7 h for AXDX. AST mean time was
35 h for VITEKV
R
2 and 9.0 h for AXDX. For ID, positive percentage agreement was 95.9% and negative percentage
agreement was 99.9%. For AST, essential agreement was 94.5% and categorical agreement was 93.5%. If AXDX
results had been available to inform patient care, 25% of patients could have been put on active therapy sooner,
while 78% of patients who had therapy optimized during hospitalization could have had therapy optimized
sooner. Additionally, AXDX could have reduced time to de-escalation (16 versus 31 h) and escalation (19 versus
31 h) compared with SOC.
Conclusions: By providing fast and reliable ID and AST results, AXDX has the potential to improve antimicrobial
utilization and enhance antimicrobial stewardship.
Introduction
Given that mortality increases with each hour of delayed treat-
ment, early recognition of sepsis and initiation of targeted antibiot-
ic therapy for patients with Gram-negative rod (GNR) bacteraemia
is crucial for optimal outcomes.1,2 Moreover, antimicrobial resist-
ance in GNRs is known to be complex.3 This results in limited thera-
peutic options, which further increases the risk of morbidity and
prolonged hospitalization, as well as mortality.1,4
Thus, there is a critical need for rapid and reliable diagnostics
that facilitate the timely selection of appropriate antimicrobials.
Integrating results from rapid laboratory methods for organism
identification (ID) and antimicrobial susceptibility testing
(AST), together with support from an antimicrobial stewardship
programme, permits clinicians to streamline therapy decisions.3,5–7
This allows timely provision of life-saving treatment, along with de-
escalation from broad-spectrum therapy,7 which can lead to
decreased length of hospital stay, reduced hospital costs and
improved patient outcomes.1,4,8–12
The Accelerate PhenoTM system (AXDX) is a new technology
that quickly identifies the most common organisms in blood-
stream infections (BSIs) using fluorescence in situ hybridization
and morphokinetic cellular analysis to provide fast AST results.13
This technology has proven to be a useful tool to provide rapid and
reliable ID and AST results,14–22 but questions remain regarding its
potential clinical impact. Unlike other rapid diagnostics, AXDX pro-
vides phenotypic AST results including MICs, a format familiar to
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clinicians,23 potentially prompting antibiotic de-escalation ahead
of an active stewardship intervention.
Our primary study objective was to compare the ID/AST per-
formance and time to result (TTR) of AXDX with current laboratory
standard of care (SOC) methods. Secondarily, we assessed the re-
lationship between TTR and the projected times to antibiotic escal-
ation, de-escalation and active and optimal therapy when using
AXDX results for patients with GNR bacteraemia.
Materials and methods
Study design and population
A prospective study evaluating ID/AST performance and TTR of AXDX com-
pared with current SOC for samples of GNR bacteraemia was conducted at
Indiana University Health Pathology Laboratory (Indianapolis, IN, USA).
Additionally, an evaluation of whether the implementation of AXDX could
theoretically lead to improvements in times to antibiotic escalation and de-
escalation, as well as times to active and optimal therapy, was retrospect-
ively assessed by clinical review. Patients seen at any of the Indiana
University Health Hospitals, including Riley Hospital for Children, from
September to December 2017 were eligible for inclusion if they had a
monomicrobial GNR-positive blood culture (PBC). Exclusion criteria for the
performance evaluation were polymicrobial samples, samples with off-
panel organisms, or samples from patients with recurrent bacteraemia
within 30 days. For the theoretical clinical review, exclusion criteria removed
samples with an off-panel organism, contaminated/impure growth, pres-
ence of a concurrent infection site that showed at least one organism not
isolated from blood, polymicrobial samples or samples from patients who
died within 24 h of PBC (Figure 1).
Pathogen ID, AST and TTR
Patient blood samples were collected using aerobic, anaerobic or paediatric
blood culture bottles and incubated in the BACTECV
R
FX blood culture moni-
toring system. Gram staining was performed after a blood culture bottle
flagged positive, followed by sub-culturing to appropriate solid media
based on Gram stain results. The AXDX system (Accelerate PhenoTestTM BC
kit and software version 1.3.1.15) was run in parallel with SOC methods for
pathogen ID [VERIGENEV
R
(Luminex Corporation, Northbrook, IL, USA) and
MALDI-TOF MS using the MALDI BiotyperV
R
system (Bruker Daltonics,
Fremont, CA, USA)] and AST [VITEKV
R
2 system: GN73 cards (bioMe´rieux,
Durham, NC, USA)]. All potential ESBL-producing isolates were initially
flagged on the VITEKV
R
2 system, followed by confirmatory testing using the
CLSI ESBL disc diffusion test from isolated colonies.24 VERIGENEV
R
results
were reviewed for each confirmed ESBL-producing isolate, specifically for
the presence of the CTX-M resistance gene. Timing calculations included
adjustments to account for delays in setup and reporting times between
SOC and AXDX.
Theoretical clinical data and outcomes
Demographic and clinical data were collected on eligible patients (Figure 1).
Charts were retrospectively reviewed by an infectious diseases clinician or
pharmacist to assess potential timing of changes in antimicrobial interven-
tions that could have been made if AXDX AST results had been available.
These included escalating therapy when appropriate, starting active or opti-
mal therapy, and de-escalating unnecessary therapy. The review included
adjudicated ID and AST results from the performance evaluation portion of
the study and was conducted under the assumption that testing with AXDX
was completed and results were acted on by the antimicrobial stewardship
team 24 h/day. One hour was added to the AXDX AST report time to ac-
count for technologist review and reporting time. Patients with antimicro-
bial intervention occurring after the theoretical AXDX AST report time were
assumed to have had that intervention time reduced by the difference be-
tween the theoretical AXDX AST report time and the actual SOC AST report
time. If an intervention time was eligible for a reduction due to earlier AXDX
AST, the reduction was limited such that the intervention would not occur
sooner than the theoretical AXDX AST report time for that patient. Cases
that did not fall within evidence-based antimicrobial stewardship pro-
gramme guidelines5 were adjudicated by an infectious diseases physician.
Active therapy was defined as the first antimicrobial dose to which the or-
ganism was susceptible by conventional antimicrobial testing. Optimal
therapy was defined as the earliest optimal (‘institution preferred’) dose of
antimicrobial from time of blood culture positivity. Times to active and opti-
mal therapy were compared with times when AXDX ID and AST results
were available. Escalation therapy was conversion to an antimicrobial with
a broader spectrum of activity while de-escalation was conversion to an
antimicrobial with a narrower spectrum of activity.
Statistical analysis
Positive percentage agreement (PPA) and negative percentage agreement
(NPA) between AXDX and SOC ID results were calculated for on-panel target
organisms. Essential agreement (EA), categorical agreement (CA), major
errors (ME) and very major errors (VMEs) were also calculated between
AXDX and SOC AST results. CA was defined as susceptible, intermediate or
175 enrolled samples 26 excluded samples:
12 polymicrobial samples
9 monomicrobial off-panel organisms
2 monomicrobial Gram-positive organisms
2 replicate samples
1 unviable sample (no SOC ID) 
39 non-reviewed cases:
18 seeded isolates (non-patient samples)
4 patients deceased within 24 h of PBC
3 contaminated/impure growth samples
11 AXDX AST non-reporta
2 VITEK® 2 non-report
2 VERIGENE® non-reporta
110 reviewed patient cases:
27 paediatric (≤21 years), 83 adult (>21 years)
13 MDR cases (ESBL)
Monomicrobial GNR culture by SOC
ID results reported on AXDX & MALDI & VERIGENE®
AST results reported on both AXDX & VITEK® 2
Patient survived at least 24 h after bottle positivity
149 monomicrobial GNR samples evaluated for
performance
a1 case had both an AXDX AST and VERIGENE® ID non-report
Figure 1. Flow diagram of study design and population inclusivity criteria.
Phenotypic susceptibility testing in bloodstream infections JAC
i17
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/Supplem
ent_1/i16/5300219 by IU
PU
I U
niversity Library user on 05 M
arch 2019
resistant results that matched between AXDX and SOC based on 2016 MIC
breakpoints set by CLSI.24 EA was defined as agreement of MICs within+1
doubling dilution between AXDX and SOC. A VME occurs when a sample is
called resistant by SOC and susceptible by AXDX. An ME occurs when a sam-
ple is called susceptible by SOC and resistant by AXDX. Samples with VMEs
or MEs were adjudicated by performing broth microdilution (BMD), which is
the gold standard method for AST.
Statistical analyses were performed with SciPy,25 using the Python pro-
gramming language.26 Statistical analyses comparing independent quanti-
tative variables (e.g. TTR of patient results compared between AXDX and
SOC methods) were performed using the two-sided Mann–Whitney U-
test.27 Computed probability less than the significance level (a) of 0.05 was
considered statistically significant. Where relevant, mean (l) and standard
deviation (r) are noted.
Results
AXDX performance evaluation
After excluding 26 samples, 149 samples, including 18 seeded iso-
lates (non-patient samples), 32 fresh paediatric (age 21 years)
samples and 99 fresh adult (age.21 years) samples from patients
with monomicrobial GNR bacteraemia, were available for perform-
ance evaluation (Figure 1). PPA was 95.9% and NPA was 99.9% for
ID (Table 1). There were six false-negatives (three Enterobacter
spp., one Proteus spp., one Citrobacter spp. and one Pseudomonas
aeruginosa). The VERIGENEV
R
system did not detect Enterobacter
gergoviae or Klebsiella variicola in two different samples, which
were detected by AXDX (identified as Enterobacter spp. and
Klebsiella spp., respectively). Following discrepancy adjudication
testing via BMD, EA was 94.5% and CA was 93.5%. SOC in AST was
predominantly the VITEKV
R
2 system with confirmatory Etests for
two cases (Table 2). Eleven percent (16/149) of samples were
found to be ESBL producers. AXDX had an overall agreement rate
of 93.7% for both EA and CA when comparing AST from the VITEKV
R
2 system with these specific isolates (data not shown).
Based on discrepancy adjudication via BMD, three initial AXDX
VMEs were adjudicated to one VME against AXDX for piperacillin/
tazobactam (Table 2), and one ME and one minor error against
VITEKV
R
2 for ampicillin/sulbactam and cefepime, respectively.
Sixteen initial AXDX MEs were adjudicated to six MEs against AXDX
(Table 2) and five VMEs against VITEKV
R
2 (including two for ceftazi-
dime and two for cefepime with ESBL Escherichia coli and one for
aztreonam). This indicates that AXDX tended to overcall resistance
while the VITEKV
R
2 system tended to overcall susceptibility for the
discrepancy-adjudicated combinations. The remaining five initial
AXDX MEs were adjudicated to minor errors (two for ampicillin/sul-
bactam, two for cefepime and one for ceftazidime).
Timing/workflow results
Despite highly variable organism growth time from collection to
positive culture (Figure S1, available as Supplementary data at JAC
Online), AXDX had a mean instrument run time of 1.3 h for ID from
time of set-up, which was consistent among runs (r"0.01 h), com-
pared with 2.0 h for the VERIGENEV
R
system, which was also con-
sistent among runs (r"0.4 h) (Table 3). Mean time for MALDI-TOF
MS confirmatory testing was 21 h from time of positivity and was
variable (r"7.2 h). AXDX required a mean time of 6.6 h from time
of set-up and 9.0 h from time of positivity for AST, compared with
9.2 and 35 h, respectively, for the VITEKV
R
2 system. (Table 3). AXDX
instrument run time for AST was also consistent (r"0.05 h) com-
pared with the VITEKV
R
2 system (r"1.4 h). AXDX decreased the ini-
tial time required to prepare PBCs with GNRs from up to 30 min to
nearly 3 min, with the potential to save45 min in total technolo-
gist time required for SOC methods.
Microbiology results
A total of 149 pathogens were isolated, with E. coli and Klebsiella
spp. being the most frequently isolated GNRs. As indicated earlier,
11% (16/149) of the isolates were ESBL producers. Of these 16, 1
(6.3%) did not carry the CTX-M resistance gene marker. Nine
organisms not present on the VERIGENEV
R
and AXDX ID panels
made up 5.5% of total monomicrobial GNR cultures tested (prior to
their exclusion in the analysed dataset) and included one each of
the following organisms: Bacteroides fragilis, Salmonella spp.,
Shewanella spp., Dialister spp., Bacteroides thetaiotaomicron,
Burkholderia gladioli, Pantoea calida, Achromobacter xylosoxidans
andAeromonas spp.
Patient characteristics
Following exclusions, 110 monomicrobial GNR patient samples,
including 27 fresh paediatric (age 21 years) and 83 fresh adult
(age.21 years) samples, were available for chart review (Figure 1).
Demographic and other characteristics for these patients are sum-
marized in Table 4. The sources of bacteraemia were most com-
monly genitourinary (38.2%), intra-abdominal (25.5%) and central
vascular catheters (14.5%), followed by skin/soft tissue (3.6%),
respiratory (2.7%), bone/joint (1.8%), cardiac (1.8%) and other
sources (0.9%). Additionally, 10.9% of sources were unidentified.
Theoretical clinical data
AXDX-derived AST results (minimum of 9.0 h after positivity) for all
cases showed a theoretical mean time to de-escalation from time
of positive culture of 0.66 days (16 h) compared with 1.3 days
(31 h) for current SOC (P,0.001) (Figure 2d). For cases involving
ESBL isolates, theoretical mean time to de-escalation was
0.91 days (22 h) using AXDX results compared with 1.7 days (41 h)
Table 1. ID performance of AXDX versus MALDI-TOF MS and VERIGENEV
R
system
Microbe PPAa NPAb
Escherichia coli 64/64 (100%) 83/83 (100%)
Klebsiella spp. 32/32 (100%) 115/116 (99.1%)
Enterobacter spp. 16/19 (84.2%) 130/130 (100%)
Proteus spp. 4/5 (80%) 144/144 (100%)
Citrobacter spp. 4/5 (80%) 144/144 (100%)
Serratia marcescens 2/2 (100%) 147/147 (100%)
Acinetobacter baumannii 4/4 (100%) 145/145 (100%)
P. aeruginosa 16/17 (94.1%) 131/131 (100%)
Total 142/148 (95.9%) 1039/1040 (99.9%)
aOne indeterminate result (E. coli) was excluded from PPA calculation.
bThree indeterminate results (one each for E. coli, Klebsiella spp. and
P. aeruginosa) were excluded from NPA calculation.
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for SOC (P"0.53) (Figure 3d). With respect to theoretical escalation
events from time of blood culture positivity, patients could have
been escalated on average by 0.81 days (19 h) using AXDX results
compared with 1.3 days (31 h) for SOC (P"0.11) (Figure 2c). For
ESBL cases, mean AXDX escalation was 0.28 days (6.7 h) compared
with 0.47 days (11 h) for SOC methods (P"0.16) (Figure 3c).
Despite current SOC reporting (call to clinician after Gram stain),
25% (28/110) of the patients were not on active therapy at the
time AXDX AST results were theoretically available (minimum 9.0 h
after positivity), and therefore could have theoretically been acted
upon sooner. Overall, mean time to active therapy with current
SOC was 0.04 days (1 h), where AXDX could have been 0.19 days
(4.6 h, P"0.58) (Figure 2a). Theoretical mean time to active ther-
apy for ESBL isolates was 0.26 days (6 h) using AXDX results com-
pared with 0.61 days (15 h) for SOC (P"0.14) (Figure 3a).
Fifty-nine percent of reviewed cases (65/110) had therapy opti-
mized during hospitalization, and of these 78% (51/65) could have
theoretically been put on optimal therapy sooner with AXDX AST
results. Mean time to optimize therapy with current SOC was
1.6 days (38 h), where AXDX could have been 0.85 days (20 h,
P"0.001) (Figure 2b). For ESBL isolates, theoretical mean time to
optimization was 0.32 days (7.7 h) using AXDX results compared
with 0.7 days (17 h) for SOC (P"0.10) (Figure 3b).
To evaluate potential clinical benefits of rapid AST results, a pre-
liminary simple linear regression analysis was performed in the
paediatric and adult populations to determine whether faster opti-
mization of antimicrobial therapy (within 3 days of PBC) could lead
to an overall decrease in total days of therapy. In the paediatric
population, each day of reduction in the time to optimal patient
therapy could correlate to a 2.0 day reduction in hospital-
administered therapy time across all paediatric patients, and a
3.4 day reduction for patients on a general ward (Figure S2a). The
adult population showed substantial variation in time to therapy
optimization, ranging from 1 day prior to 7 days after PBC. The
same linear regression across this population showed a limited ef-
fect of therapy optimization, with only a 0.7 day reduction across
all adult patients. When focusing on adult patients with lower
Charlson comorbidity index (CCI) scores, however, simple regres-
sion showed a 1.9 day reduction in total therapy for CCI 2 in this
population (Figure S2b).
Discussion
The major findings of this study are that AXDX has the potential to
significantly reduce time to pathogen ID and AST results for mono-
microbial BSIs compared with SOC, and improve times to antibiotic
de-escalation and active and optimal therapy.
Multiple studies have verified the accuracy and timing by which
AXDX provides pathogen ID and AST;14–22 however, there are few
data on the potential impact this novel assay has on clinical out-
comes. Thus, our findings in this earliest cohort of investigations
demonstrate the hypothetical impact of AXDX results on time to
active and optimal therapy. Additionally, our results show the po-
tential utility of AXDX to enhance antimicrobial stewardship by pro-
moting faster antimicrobial de-escalation, which has been
associated with improved clinical outcomes.28,29
Given the antimicrobial resistance crisis, there is a critical need
for rapid and reliable diagnostics that permit the timely selection
of antimicrobial therapy and enhanced antibiotic stewardship.
During the empirical treatment period, studies show that many
patients with both community- and healthcare-acquired bacter-
aemia often receive incorrect, inadequate or excessively broad-
Table 2. AST performance of AXDX compared with standard methodsa, following adjudication
Antibiotic EA CA VME ME S I R
Ampicillin/sulbactam 84/93 (90.3%) 74/93 (79.6%) 0 1 47 14 32
Piperacillin/tazobactam 94/103 (91.3%) 97/103 (94.2%) 1 0 86 2 15
Cefepime 122/134 (91.0%) 117/134 (87.3%) 0 1 105 7 22
Ceftazidime 113/132 (85.6%) 111/132 (84.1%) 0 2 97 3 32
Ceftriaxone 115/115 (100%) 113/115 (98.3%) 0 0 81 1 33
Meropenem 123/128 (96.1%) 123/128 (96.1%) 0 2 114 0 14
Amikacin 125/127 (98.4%) 126/127 (99.2%) 0 0 121 1 5
Gentamicin 125/131 (95.4%) 130/131 (99.2%) 0 0 111 1 19
Tobramycin 126/131 (96.2%) 125/131 (95.4%) 0 0 108 7 16
Ciprofloxacin 131/132 (99.2%) 130/132 (98.5%) 0 0 93 1 38
Aztreonam 1/1 (100%) 1/1 (100%) 0 0 0 0 1
Total 1159/1227 (94.5%) 1147/1227 (93.5%) 1 6 963 37 227
aVITEKV
R
2 (n"147) and Etest (n"2).
Table 3. Mean time to assay result by method (n"110)
Assay Method
Instrument
run time (h)a
Time from
positivity (h)a
ID VERIGENEV
R
2.0+0.4 4.4+1.7
MALDI-TOF MS NA 21+7.2
AXDX 1.3+0.01 3.7+1.7
AST VITEKV
R
2 9.2+1.4 35+7.7
AXDX 6.6+0.05 9.0+1.7
NA, not applicable.
aTimes presented are mean (l)+standard deviation (r). n"110 for all
results, P,0.001 between timing results for all listed methods in each
assay group.
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spectrum therapy.11,30–32 Inappropriate and widespread use of
broad-spectrum antimicrobials not only contributes to patients
enduring drug toxicity, increased lengths of stay, secondary infec-
tions and additional costs, but also increases the frequency of
antimicrobial-resistant organisms.1,31,33 Poorly targeted therapy
for a BSI may also increase a patient’s risk of developing sepsis
after the primary hospitalization.34
Our results showed that AXDX has the potential to enhance the
capacity for antimicrobial de-escalation, compared with current
standard methods (16 compared with 31 h, P,0.001). However,
Table 4. Characteristics of case-reviewed patient populations
Category Description Total cases (n"110) Paediatric cases (n"27) Adult cases (n"83)
Pathogen E. coli 56 (51%) 8 (30%) 48 (58%)
Klebsiella spp. 26 (24%) 10 (37%) 16 (19%)
Enterobacter spp. 11 (10%) 6 (22%) 5 (6%)
P. aeruginosa 9 (8%) 3 (11%) 6 (7%)
Acinetobacter baumannii 3 (3%) – 3 (4%)
Citrobacter spp. 3 (3%) – 3 (4%)
Proteus spp. 2 (2%) – 2 (2%)
Gender female 50 (45%) 13 (48%) 37 (45%)
male 60 (55%) 14 (52%) 46 (55%)
Age 1 month ,1 year 5 (5%) 5 (19%) –
1 year18 years 19 (17%) 19 (70%) –
.18 years21 years 3 (3%) 3 (11%) –
.21 years ,50 years 14 (13%) – 14 (17%)
50 years ,60 years 21 (19%) – 21 (25%)
60 years ,70 years 20 (18%) – 20 (24%)
70 years ,80 years 18 (16%) – 18 (22%)
80 years 10 (9%) – 10 (12%)
Admission service haematology/oncology 13 (12%) 8 (30%) 5 (6%)
critical care 10 (9%) 2 (7%) 8 (10%)
transplant 14 (13%) 5 (19%) 9 (11%)
general wards 73 (66%) 12 (44%) 61 (73%)
Intensive care ICU visit during therapy 36 (33%) 7 (26%) 29 (35%)
no ICU visit 74 (67%) 20 (74%) 54 (65%)
9.0 P= 0.58 *P= 0.001 P= 0.11 *P< 0.001
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σ = 1.9 d (46 h)
Optimal therapy (n= 65)
AXDX
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Therapy de-escalation (n= 86)
AXDX
m= 0.66 d (16 h)
σ = 1.2 d (29 h)
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
–1.0
–2.0
–3.0
–4.0
–5.0
–6.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
–1.0
–2.0
–3.0
–4.0
–5.0
–6.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
–1.0
–2.0
–3.0
–4.0
–5.0
–6.0
*Indicates significant difference (P< 0.05)
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Figure 2. All-patient therapy intervention times. SOC compared with theoretical AXDX for (a) active therapy, (b) optimal therapy when possible, (c)
first escalation of therapy when required and (d) first de-escalation of therapy when possible. Box plots display median and IQR with tails indicating
the minimum and maximum of observed values, and the notes below show the mean (l) and standard deviation (r). The grey dotted line represents
mean AXDX AST time (9.0 h) for reference.
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for more complex cases involving confirmed ESBL isolates, this ef-
fect did not reach significance (22 compared with 41 h, P"0.53).
These findings may be explained by the low sample size (n"8), or
by the fact that more-resistant organisms generally require escal-
ation, coupled with the assumption that physicians may be more
hesitant to de-escalate until clinical improvement is observed.
Conversely, rapid AST was less likely to affect an escalation event
across the general patient population than for patients with an
ESBL-producing organism.
At the time of PBC detection, our study showed that 25% of
patients could have been put on active therapy sooner had the
AXDX AST results been made available. Interestingly, rapid AST did
not have a statistically significant effect on active therapy across
all patients (P"0.58). But for more resistant cases (i.e. ESBLs), there
was a notable increase in the average time to active therapy (1.1 h
for all patients compared with 15 h for ESBLs). Additionally, there
was a notable decrease in variability of the AXDX results: r"19 h
for all patients compared with 9.6 h for ESBLs. While these results
are based on a low sample size, the increased average time sug-
gests that empirical therapy is less likely to be active against resist-
ant organisms, and the reduced AXDX variability implies that rapid
and consistently timed AST results such as those produced by
AXDX would be useful when selecting an appropriate active treat-
ment for resistant organisms.
For cases of non-ESBL and ESBL isolates, rapid AST would signifi-
cantly improve time to optimal therapy. Our clinical review
revealed that 78% of patients who received optimized therapy
could have had therapy optimized earlier had AXDX AST results
been available. Additionally, we found that each day required to
optimize patient therapy in the paediatric population could correl-
ate to a reduction of 2.0 and 3.4 days in hospital-administered
therapy across all paediatric patients and in general ward paediat-
ric patients, respectively. For adults, the effect of optimization and
reduction in total days of antimicrobial therapy was only shown in
less critically ill patients (CCI 2). Future prospective studies on
more detailed populations are needed to develop more sophisti-
cated models of antibiotic therapy versus CCI and/or paediatric se-
verity of illness metrics. Overall, however, these data illustrate the
potential of AXDX to enable treating physicians and stewards to
optimize therapy for patients with microbial infections (including
MDR organisms) sooner, to promote reduction in hospital-adminis-
tered therapy and to reduce patient risk.
Clinical microbiology laboratories have utilized various rapid
diagnostics for BSIs with GNRs, including VERIGENEV
R
, BioFire, the
FilmArrayV
R
Blood Culture Identification (BCID) Panel and MALDI-
TOF MS. These diagnostic modalities have been shown to decrease
mortality and shorten hospital stays, even more so if they are used
in conjunction with a robust stewardship programme.10 Because
these modalities are unable to completely replace traditional
microbiology techniques, the complexity of laboratory workflow
must increase to fully glean these clinical benefits. Furthermore,
data supporting de-escalation are much less robust with molecu-
lar AST detection, reflecting the lack of confidence and under-
standing physicians have for molecular results.5,35,36
Similar to other studies,14–22 this study shows that AXDX pro-
vides reliable results for ID and AST that are comparable to other
standard testing, such as molecular, proteomics-based and con-
ventional phenotypic methods. There were, however, instances in
which SOC methods for routine ID and AST were recommended by
AXDX (11% of the time). This included AST non-reportable results
(n"11, 7.3%) and ‘off-panel’ organisms not identified by AXDX
(n"9, 5.5%). Consequently, like other rapid diagnostics, AXDX will
not be able to replace traditional modalities for all ID and AST
combinations, particularly for off-panel or polymicrobial cul-
tures.16,18,23 However, upon evaluation of our workflow, AXDX
substantially reduced overall ‘hands-on’ time for laboratory tech-
nologists, improving our workflow (decreasing setup and process-
ing time 10-fold, from nearly 30 min for SOC to 3 min for AXDX),
with the potential to save 45 min in total technologist time
required for SOC methods.
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Figure 3. ESBL-patient therapy intervention times. SOC compared with theoretical AXDX for (a) active therapy, (b) optimal therapy when possible, (c)
first escalation of therapy when required and (d) first de-escalation of therapy when possible. Box plots display median and IQR with tails indicating
the minimum and maximum of observed values, and the notes below show the mean (l) and standard deviation (r). The grey dotted line represents
mean AXDX AST time (9.0 h) for reference.
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This study has several limitations. First, the study site is a qua-
ternary referral centre, with multiple state-wide satellite hospitals,
caring for a varied patient mix including immunocompromised
patients and a broad spread of resistance patterns, making these
findings less generalizable to all healthcare settings. These find-
ings will have the greatest impact in locales with similar practices
and resources to our study site. Second, our study population was
limited to GNR BSIs and did not address Gram-positive or yeast
BSIs. While this does limit our study population, GNR BSIs have
been shown to have increasing complexity of antimicrobial resist-
ance,1,3–5,23 along with infectious disease physicians ranking this
type of infection as one of the most unmet needs in pathogen
diagnostics.37 Third, polymicrobial samples as indicated by Gram
stain (10% of all PBCs) were excluded due to limitations on AXDX
producing AST for all pathogens in these samples.16,19
Consequently, for this select subset, not all aspects of patient care
that could have influenced clinical outcomes were captured.
Furthermore, the lack of polymicrobial infections being tested (in
addition to excluding Gram-positive and yeast BSIs) may have
increased the performance of AXDX with respect to other studies.
It should be noted that AXDX’s potential for clinical impact with
Gram-positive bacteraemia has been shown in recent publica-
tions.16,18–20 Fourth, several assumptions (described in the
Materials and methods section) regarding the potential clinical im-
pact of decreased TTR, including how the theoretical data used
were derived from retrospective chart review, limit our ability to
infer the true result times and clinical impact. Fifth, optimal or ‘in-
stitution preferred’ therapy varies among different institutions,
which may lead to these results being less generalizable to other
healthcare settings. Sixth, the overall cost of implementing the
AXDX technology was not assessed. Although AXDX can function
as a standalone test for a large percentage of clinical isolates, it
cannot remove the need for subculture of PBCs to ensure detection
of other off-panel organisms (5.5%, not including polymicrobial
samples).16,18,23 Finally, TTR and percentage agreement values
were only compared with SOC modalities at the test site. Clinical
studies comparing AXDX with rapid diagnostic tests implemented
at other laboratories, specifically those that include molecular AST,
are needed to evaluate the true impact of AXDX’s phenotypic AST
results.
Conclusions
AXDX significantly reduces ID/AST TTR for PBC specimens, and thus
can potentially aid in effective antimicrobial stewardship. Our find-
ings highlight the potential clinical benefits of utilizing rapid pheno-
typic susceptibility testing to allow earlier modification of empirical
therapy. Given the nature of this study, the true clinical significance
of these time differences is unknown. However, given the strong
evidence that each hour of delayed treatment in patients with
GNR bacteraemia increases mortality,1,2 it stands to reason that
these time differences could have a significant clinical impact.
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